Kirchner J T
Lancaster General Hospital, Pennsylvania.
Am Fam Physician. 1994 Aug;50(2):335-41.
The human parvovirus B19 has been identified as the causative agent in several diseases, including the benign childhood condition erythema infectiosum (fifth disease), a polyarthropathy that occurs in adults, aplastic crisis and hydrops fetalis. The virus has also been associated with numerous other hematologic, neurologic and rheumatic conditions. Except for the potential of neonatal death due to fetal hydrops, the prognosis of patients with parvovirus infection is generally good. The diagnosis of B19 infection may be established on clinical grounds but often requires confirmation with serum antibody testing. Treatment strategies may include supportive care, analgesic medications, transfusions with red blood cells or administration of intravenous immunoglobulin, depending on the clinical circumstances.
人类细小病毒B19已被确认为多种疾病的病原体，包括儿童良性疾病传染性红斑（第五病）、成人发生的多关节炎、再生障碍性危象和胎儿水肿。该病毒还与许多其他血液学、神经学和风湿性疾病有关。除了因胎儿水肿导致新生儿死亡的可能性外，细小病毒感染患者的预后通常良好。B19感染的诊断可根据临床情况确定，但通常需要通过血清抗体检测来证实。治疗策略可能包括支持性护理、止痛药物、红细胞输血或静脉注射免疫球蛋白，具体取决于临床情况。
